# Focused Antibody and DNA Production for CVV Investigation

Canonical: https://abierto.us/opportunities/75d30124q78087

- Solicitation number: 75D30124Q78087
- Notice type: Combined synopsis and solicitation
- Status: Awarded to Genscript USA Inc.
- Department: Department of Health and Human Services
- Agency: Centers for Disease Control and Prevention
- Contracting office: CDC Office of Acquisition Services (75D301)
- NAICS: 325414 Biological Product (except Diagnostic) Manufacturing
- Product or service code: 6550 In Vitro Diagnostic Substances, Reagents, Test Kits and Sets
- Place of performance: Atlanta, Georgia
- City: Atlanta. https://abierto.us/cities/atlanta-ga-1304000
- First posted: August 2, 2024
- Last posted: September 3, 2024
- SAM.gov: https://sam.gov/workspace/contract/opp/99c58865e31940b68417a518c13a2d23/view

## Description

This amendment is re-opening the solicitation to allow for further competition. All quotes shall be due by 3:00 PM EDT on Tuesday September 10, 2024. Additional questions, if any, are due by 3:00 PM EDT on Thursday September 5, 2024. CDC Influenza Division (ID) is responsible for the development of Candidate Vaccine Viruses (CVV) based on circulating and novel influenza strains. CVVs are reassortant viruses which are used as the starting materials for seasonal and pandemic vaccines.

To facilitate the development of CVVs, the CDC uses synthetic genes to transcribe viral genes to produce CVVs. Interactions between viruses and host proteins can elucidate molecular properties of viruses not readily apparent by other means. Expressing proteins from engineered plasmids is the foundation of most downstream assays utilized in this regard.

Accordingly, the Influenza Division requires synthetic genes, produced by de novo synthesis or modifications of existing templates through mutagenesis, and other genetic products to be developed routinely based on the constant changes in the genetic makeup of the circulating and novel viruses. These changes are unpredictable and cannot be identified until the viruses are isolated from patients or infected animals.

## Award on USAspending

- Recipient: Genscript USA Inc. (UEI KVLBRRAQ6UX1)
- Contract: 75D30124P19489, purchase order
- Obligated: $227,348.40
- Competition: Competed Under SAP, 3 offers received
- Link: solicitation number 75D30124Q78087 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record: https://www.usaspending.gov/award/CONT_AWD_75D30124P19489_7523_-NONE-_-NONE-/


## Publications

- August 2, 2024: Combined synopsis and solicitation, due August 21, 2024 at 5:00 PM EDT. Notice 1262d58d2f174f54b0d65b601901596b. https://sam.gov/workspace/contract/opp/1262d58d2f174f54b0d65b601901596b/view
- August 21, 2024: Combined synopsis and solicitation, due August 27, 2024 at 4:00 PM EDT. Notice 95f3377f9a06402299f8fb9b5dbb4765. https://sam.gov/workspace/contract/opp/95f3377f9a06402299f8fb9b5dbb4765/view
- August 23, 2024: Combined synopsis and solicitation, due August 27, 2024 at 3:00 PM EDT. Notice 9b9e061ee8a74237b2785f1c2e7a52f8. https://sam.gov/workspace/contract/opp/9b9e061ee8a74237b2785f1c2e7a52f8/view
- September 3, 2024: Combined synopsis and solicitation, due September 10, 2024 at 3:00 PM EDT. Notice 99c58865e31940b68417a518c13a2d23. https://sam.gov/workspace/contract/opp/99c58865e31940b68417a518c13a2d23/view

## Points of contact

- Jennifer Gartzke, xuy7@cdc.gov, 4044980020

---
Source: SAM.gov Contract Opportunities bulk extract and USAspending.gov award data. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/75d30124q78087.